Replies to post #246291 on Biotech Values

[rfj1862]

HTN had multiple blockbuster drugs w differing MOAs, along w combination regimens that in their own right became blockbusters
Aren't you arguing my side here w this analogy

The *current* hypertension market, not the good old days.

There is very little innovation in hypertension these days because there is no point in spending hundreds of millions for clinical trials for drugs that are at best an incremental improvement over current agents that cost pennies per dose.

For this reason, I'd expect that when and if I need hypertension medications I'll be stuck with the same crappy drugs my grandparents take.

Similarly if a VK2809-based generic were to enter the market, it would kill every other NASH drug and make development of new agents for NASH far less attractive. Remember one of the major pluses of NASH is that it is a more or less completely unaddressed market at this point.

My only point here is that either Sentiv Capital picked up on something that literally nobody else has and all NASH companies (not just VKTX) are extremely overvalued or the insight has no impact.